Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on developing cancer therapeutics, has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare. The award recognizes the company's innovative approach to addressing cancer drug resistance, a major challenge in oncology that limits the effectiveness of existing therapies.
The Pinnacle Awards, which honor outstanding achievements in healthcare, highlight Kairos Pharma's strategy centered on resistance-modulating treatments. The company's lead candidate, ENV-105 (carotuximab), is an antibody designed to inhibit tumor resistance pathways and enhance the efficacy of standard therapies. By targeting CD105—a protein identified as a key driver of resistance and disease relapse—ENV-105 aims to restore the effectiveness of treatments across multiple cancer types.
Kairos Pharma is currently advancing ENV-105 in clinical trials. The drug is being evaluated in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, both areas with significant unmet medical needs. The company's combination approaches seek to improve the durability of response in patients, potentially offering new hope for those with treatment-resistant cancers.
The recognition from the Pinnacle Awards underscores the potential impact of Kairos Pharma's research. As noted in the press release, ENV-105 has not yet been approved as safe or effective by the U.S. Food and Drug Administration or any other comparable foreign regulator. However, the award highlights the importance of the company's work in overcoming drug resistance, which remains a critical barrier to effective cancer treatment.
For more information about Kairos Pharma and its latest news, visit the company's newsroom at https://ibn.fm/KAPA. The full press release regarding the Pinnacle Award can be accessed at https://ibn.fm/ghPJC.
Based in Los Angeles, California, Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer. The company's focus on resistance-modulating therapies positions it at the forefront of oncology innovation, with the potential to improve outcomes for patients who have limited treatment options.
